Acesso livre
Acesso livre

Hematologia

Estudo de braço único fase 2 | Rituximabe, lenalidomida e ibrutinibe em pacientes com linfoma de grandes células B recém-diagnosticado.

29 Ago, 2022 | 17:30h

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 


Resultados de longo prazo de um estudo randomizado | Lenalidomida com rituximabe vs. rituximabe em quimioterapia seguida de rituximabe de manutenção no linfoma folicular avançado não tratado.

29 Ago, 2022 | 17:27h

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma – Journal of Clinical Oncology

Comentários:

First-Line Lenalidomide/Rituximab vs Rituximab/Chemotherapy With Rituximab Maintenance for Advanced Follicular Lymphoma – The ASCO Post

Lenalidomide Plus Rituximab Represents Acceptable Chemo-Free Alternative for Untreated Advanced Follicular Lymphoma – OncLive

 

Comentário no Twitter

 


Revisão | Reações à transfusão sanguínea.

29 Ago, 2022 | 13:38h

Blood Transfusion Reactions—A Comprehensive Review of the Literature including a Swiss Perspective – Journal of Clinical Medicine

 


Estudo de braço único fase 2 | Segurança e eficácia do mitapivate, ativador oral da piruvatequinase, em adultos com alfatalassemia ou betatalassemia não dependente de transfusão.

22 Ago, 2022 | 16:28h

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study – The Lancet (link para o resumo – $ para o texto completo)

Comentário: PK Modulator Shows Promise in Thalassemia — In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients – MedPage Today (necessário cadastro gratuito)

 


Diretriz | Uso de plasma convalescente de COVID-19.

22 Ago, 2022 | 16:08h

Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma – Annals of Internal Medicine

Editorial: The Fast and the Furious: Chasing a Clinical Niche for COVID-19 Convalescent Plasma – Annals of Internal Medicine

Comunicado de imprensa: The AABB releases clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma – American College of Physicians

 


M-A | Eficácia e segurança da anticoagulação com heparina em dose plena em pacientes de COVID-19 internados e não críticos.

16 Ago, 2022 | 13:04h

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials – Journal of Thrombosis and Thrombolysis

Conteúdos relacionados:

Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with Covid-19: a systematic review and meta-analysis – Open Forum Infectious Diseases

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?

 


Revisão | Plasmaférese na UTI.

16 Ago, 2022 | 12:58h

Plasma exchange in the intensive care unit: a narrative review – Intensive Care Medicine

 

Comentário no Twitter

 


M-A | Intervenções para reduzir infecções em pacientes com malignidades hematológicas.

16 Ago, 2022 | 12:39h

Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis – Blood Advances

Comentário: Prophylactic Immunoglobulin, Vaccinations May Reduce Infections in Hematologic Malignancies – AJMC

 


Resultados de longo prazo de estudo randomizado fase 2 | Elotuzumabe com pomalidomida e dexametasona para mieloma múltiplo recidivante/refratário.

16 Ago, 2022 | 12:35h

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial – Journal of Clinical Oncology

Estudo original: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – New England Journal of Medicine

 


Diretriz de consenso | Tromboprofilaxia para prevenção de tromboembolismo venoso em pacientes internados com cirrose.

15 Ago, 2022 | 13:34h

Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH – Journal of Thrombosis and Haemostasis

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.